[email protected]
Apparently we are doing something right as we have received repeated recognition for the quality of our budding business: Our license application for Granulysin-Dendritic Cells was accepted by the NIH and posted to the federal register; We were selected as a “featured company” at Techweek Chicago’s WellTECH Summit, an event followed up with national media coverage; Orpheden’s business plan was selected as a “finalist” in the iBIO PROPEL business plan competition, giving us a chance to pitch in front of over 200 investors for the grand prize in August; We pitched during the Northwestern tech transfer office’s annual meeting to their board of directors; And we were nominated for the 13th annual Chicago Innovations Awards, a prestigious entrepreneurship award given in September;
All in all, we are excited to guide Orpheden as it continues to gain momentum towards a flourishing pharmaceutical company.